






The relationship between clinical parameters and ultrasonographic enthesitis assessment in patients with spondyloarthritis

Gunay Er¹ , Deniz Palamar² , Kenan Akgün² , İbrahim Asoğlu³ , Hidayet Sarı² 

¹Department of Physical Medicine and Rehabilitation, Prof. Dr. Cemil Taşçıoğlu Şehir Hastanesi, İstanbul, Türkiye

²Department of Physical Medicine and Rehabilitation, Cerrahpaşa Medical Faculty, İstanbul University-Cerrahpaşa, İstanbul, Türkiye

³Department of Physical Medicine and Rehabilitation, Malatya Training and Research Hospital, Malatya, Türkiye

Correspondence: Gunay Er, MD.

E-mail: drgunayer@gmail.com

Received: March 19, 2023

Accepted: August 10, 2023

Published online: March 20, 2024

Citation: Er G, Palamar D, Akgun K, Asoglu I, Sari H. The relationship between clinical parameters and ultrasonographic enthesitis assessment in patients with spondyloarthritis. Arch Rheumatol 2024;39(x):1-13. doi: 10.46497/ArchRheumatol.2024.10224

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes (<http://creativecommons.org/licenses/by-nc/4.0/>).

ABSTRACT

Objectives: The study aimed to evaluate the role of ultrasonographic assessment of enthesitis in patients with spondyloarthritis (SpA) in terms of disease activity, functionality, and quality of life.

Patients and methods: Ninety SpA patients (57 males, 33 females; mean age: 37.5±9.7 years; range, 18 to 60 years) were included in cross-sectional study between November 2016 and January 2017. Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Ankylosing Spondylitis Disease Activity Score (ASDAS), Bath Ankylosing Spondylitis Functional Index (BASFI), Short Form-12 (SF-12), and Ankylosing Spondylitis Quality of Life (ASQoL) were utilized for clinical evaluation. The clinical evaluation of enthesitis was performed with the Spondyloarthritis Research Consortium of Canada (SPARCC) and Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) via an algometer calibrated to 4 kg/cm² of pressure. Ultrasound evaluation was performed according to Madrid Sonographic Enthesitis Index (MASEI). A total of 2,610 enthesal sites were examined clinically, and 1,080 were assessed ultrasonographically.

Results: A significant proportion of enthesitis (463/1,080) was detected on ultrasonographic evaluation but not with clinical enthesitis score (MASES and SPARCC). Although ultrasonographic enthesal evaluation detected enthesitis in at least one enthesal site of all patients, 35 of the patients had no enthesitis with clinical examination. The sites most frequently involved in the entheses were the proximal patellar tendon and Achilles tendon. The MASEI score did not correlate with the MASES, SPARCC, BASDAI, SF-12, and ASQoL but moderately correlated with the C-reactive protein (CRP) level (r=0.348), ASDAS-CRP (r=0.294), and BASFI score (r=0.244).

Conclusion: The association of ultrasonography scores with CRP levels and ASDAS-CRP indicates that ultrasonography is effective in detecting inflammation. The MASEI score weakly correlates with functionality but not with quality of life. Ultrasonographic evaluation is invaluable and merits to be incorporated into SpA disease scoring system.

Keywords: Disease activity, enthesitis, spondyloarthritis, ultrasonography.

An enthesis is a region where the tendon, ligament, fascia, or joint capsules adhere to the bone. The inflammatory involvement of “the enthesal organ” that consists of fibrocartilage, synovium, and bone is defined as enthesitis.¹ Enthesitis is one of the major manifestations of spondyloarthritis (SpA), and neutrophils in the enthesal organ were suggested to be responsible for the early phase of enthesitis.² Enthesitis also plays a significant role in the pathogenesis of SpA.

Pain and swelling in the enthesis allow clinical diagnosis of enthesitis. Inflammation and mechanical loading generate pain and swelling

by providing invasion of nerves and blood vessels into the enthesal organ that should be avascular and does not have plenty of nerve endings in a healthy enthesal region.³ Conventionally, clinical evaluation has been an important part of enthesitis assessment, and clinical enthesitis scoring systems have been developed to evaluate enthesitis and to standardize studies in SpA. Firstly, Mander et al.⁴ published an instrument, the Mander enthesitis index (MEI), that investigates 66 entheses and grades pain intensity on a scale of 0 to 3. MEI was time-consuming to apply and thus could not be used widely, and the Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) has been

developed by modifying MEI.⁵ MASES is achieved by palpating 13 entheses: right and left first and seventh costochondral joint, spina iliaca posterior superior, spina iliaca anterior superior, iliac crest, Achilles tendon proximal insertion, and the fifth lumbar spinous process. MASES is a valuable option with a much better feasibility.⁵ Afterward, the Spondyloarthritis Research Consortium of Canada (SPARCC) developed an enthesitis index that evaluates eight peripheral entheses bilaterally: the supraspinatus tendon insertion site, medial epicondyle, lateral epicondyle, greater trochanter, quadriceps tendon, patellar tendon, Achilles tendon, and plantar fascia.⁶ MASES and SPARCC enthesitis indexes are frequently used in studies. SPARCC includes peripheral enthesitis sites that are easy to image by ultrasound. However, one of its important shortcomings is that the SPARCC index does not contain axial enthesal regions.

Poor interobserver reliability and lack of accuracy in clinical evaluation have made imaging methods an essential part of the enthesitis examination.⁷ Conventional radiographs provide limited information about enthesal sites for the reason that they cannot visualize soft tissue, and other imaging modalities, such as magnetic resonance imaging (MRI) and ultrasound (US), have been used to reveal soft-tissue changes and inflammation. Compared to US, MRI has also the ability to evaluate bone marrow edema, which is a part of the enthesitis organ. US has considerable benefits including ease of access and inexpensive, real-time, and dynamic evaluation. US has allowed rheumatologists to diagnose, assess disease severity, and monitor changes in disease status.

In the last decade, the use of US has become widespread in the evaluation of peripheral entheses. Large-scale studies of US in SpA were first performed by Lehtinen et al.⁸ in 1994 and then by Balint et al.⁹ in 2002. In 2003, D'Agostino et al.¹⁰ first described the use of power Doppler to image hyperemia and neovascularization. The Outcome Measures for Rheumatoid Arthritis Clinical Trials (OMERACT) Ultrasound Working Group defined ultrasonographic lesions to help standardization. Enthesitis was defined as "hypoechoic and/or thickened insertion of the enthesitis close to the bone (within 2 mm from the bony cortex) which exhibits Doppler signal if active and that may

show erosions, enthesophytes/calcifications as a sign of structural damage."¹¹

Ultrasonography allows the exploration of a specific enthesitis for getting information about the local area or multiple selected entheses. Various combinations of enthesitis locations and elemental lesions form US enthesitis indexes that may demonstrate the global disease state. Several sonographic scoring systems have been developed to evaluate peripheral enthesitis. The first used US enthesitis index was the Glasgow Ultrasound Enthesitis Scoring System (GUESS), which evaluates only the enthesitis of lower limbs in greyscale.⁹ GUESS evaluates four types of lesions including thickness, bursa, erosion, and enthesophytes. Afterward, D'Agostino et al.¹⁰ first added the power Doppler signal and developed five possible stages instead of scores. In 2007, the Sonographic Enthesal Index described lesions as acute and chronic based on GUESS.¹² In 2009, the Madrid Sonographic Enthesitis Index (MASEI) was developed and has been the second most utilized index after GUESS.¹³ The use of MASEI is favored since it assesses the upper extremity and uses power Doppler. Lastly, the Belgrade Ultrasound Enthesitis Score (BUSES) was found useful for enthesitis evaluation in patients with SpA in 2015.¹⁴ Common extensor tendon enthesitis is assessed in BUSES instead of brachial triceps tendon and grades Doppler signal and erosion on 0 or 4 instead of 0 or 3 compared to MASEI.

Ultrasonographic scoring systems have been used for early diagnosis, monitoring of progression, and response to treatment. There are limited studies that aim to compare disease activity, quality of life, and functional status with ultrasonographic enthesitis assessment. These studies were performed with only one tendon or only the lower extremity or without using any scoring system. Falcao et al.¹⁵ aimed to find out whether ultrasonographic enthesitis scores are associated with disease activity and evaluated only Achilles enthesitis based on MASEI. In 2011, Hamdi et al.¹⁶ sought a correlation among clinical parameters such as disease activity, functionality, and quality of life and clinical (MASES and SPARCC) and ultrasonographic enthesitis scores that include five lower limb entheses based on no sonographic enthesitis score. In studies comparing BUSES with clinical parameters, either clinical enthesitis scores or functionality and quality of

life were not evaluated.^{17,18} In a study utilizing MASEI, authors investigate the correlation among sonographic and clinical evaluation of enthesal sites in MASEI, disease activity, and quality of life but clinical enthesitis indices were not used, functional status was neglected, and the correlation between C-reactive protein (CRP), an important marker of inflammation and disease activity in SpA, was not investigated.¹⁹ This study aimed to comprehensively evaluate many parameters, including disease activity, quality of life, functional status, clinical enthesitis scores, and ultrasonographical enthesitis assessment, with the MASEI index and to determine how valuable ultrasonographic enthesitis is to assess disease activity, functionality, and quality of life.

PATIENTS AND METHODS

Ninety SpA patients (57 males, 33 females; mean age: 37.5 ± 9.7 years; range, 18 to 60 years) who applied to the Istanbul University-Cerrahpaşa, Cerrahpaşa Medical Faculty, Physical Medicine and Rehabilitation Department, Rheumatology Clinic between November 2016 and January 2017 were enrolled in the cross-sectional study. Inclusion criteria were defined as being between 18 and 60 years old and fulfilling the 2009 Assessment of Spondyloarthritis International Society SpA criteria.²⁰ Exclusion criteria were defined as having concomitant rheumatologic disease, having a history of elbow, ankle, or knee surgery, local injection at the examination sites within six weeks, peripheral neuropathy, infection, and wound in the entheses which would be evaluated clinically and ultrasonographically. Patients who met the modified New York criteria were described as having ankylosing spondylitis, and patients who did not meet the modified New York criteria were described as having nonradiographic axial SpA.²¹ The patients were classified in accordance with cut-off values of CRP values and disease activity scales.

Clinical history was taken and physical examination was performed by the first clinician. Human leukocyte antigen-B27 positivity, CRP, and erythrocyte sedimentation rate (ESR) levels were recorded. Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Ankylosing Spondylitis Disease Activity Score (ASDAS)-CRP and ASDAS-

ESR was evaluated for disease activity, and Bath Ankylosing Spondylitis Functional Index (BASFI) was assessed for functionality. Short Form-12 (SF-12) and Ankylosing Spondylitis Quality of Life (ASQoL) was measured for quality of life. Mental Component Score (MCS) and Physical Component Score (PCS) were subscales of SF-12. The clinical evaluation of enthesitis was performed with SPARCC and MASES via an algometer (Jamar Hand Evaluation Kit, Sammons Preston Inc., Bolingbrook, IL, USA) calibrated to 4 kg/cm² of pressure. In addition to enthesitis indices, the bilateral distal triceps tendon insertions were evaluated with the same algometer and pressure.

Ultrasound evaluation

The US evaluations were performed by a 10-year experienced specialist using a MyLab70 US system (Esaote Biomedica, Genoa, Italy) with a 7-12 MHz linear probe. Power Doppler settings were standardized with a wall filter of 3, pulse repetition frequency of 750 Hz, and a Doppler frequency of 4-13 MHz. Gain was adjusted until the background signal disappeared. US examiner was blind to the patients' information, and patients were asked not to inform the sonographer about their clinics.

All patients underwent US examinations of the following bilateral six enthesal sites: the distal brachial triceps tendon, plantar aponeurosis, Achilles tendon, proximal and distal patellar tendon, and quadriceps tendon. All of the US findings were documented in accordance with MASEI.²² Each enthesitis site was scanned in two planes: longitudinal and transverse. The triceps tendon insertion was evaluated with the arm flexed at 90° and internal rotation in a sitting position. Knee enthesitis sites (quadriceps tendon, proximal, and distal patellar tendon insertions) were examined when the knee was flexed at 70°, and the ankles were fixed on the table. The Achilles tendon and plantar aponeurosis examination was performed with the patients lying prone. Doppler examination was performed with the patients' joints in neutral position to reduce tendon tension.

MASEI index evaluated five elemental lesions (scores) of enthesitis: structure (0 or 1), thickness (0 or 1), erosions (0 or 3), calcifications (0, 1, 2, or 3), bursae (only at distal patellar tendon and Achilles tendon) (0 or 1), power Doppler signal

(0 or 3).²² Calcifications were scored as 0 if it was absent, 1 if <5 mm, 2 if 5-10 mm, or 3 if they were >10 mm.²³ Bursitis was defined as a compressible by the transducer, localized anechoic or hypoechoic, well-circumscribed area at Achilles enthesis and distal patellar enthesis. Erosion was defined as a cortical breakage with a step-down contour defect in two planes. A thickness assessment was made by measuring the maximal thickness at the bone insertion site. Based on enthesis-specific values (plantar aponeurosis >4.4 mm, Achilles tendon >5.29 mm, proximal and distal patellar tendon >4 mm, quadriceps tendon >6.1 mm, and triceps enthesis >4.3), it was determined whether there was an increase in thickness. Structural evaluation was defined as pathological in the presence of any of the loss of fibrillar pattern, hypoechoic appearance, and fusiform thickening in the enthesis area. The total score ranged from 0 to 136. The MASEI-Inflammatory score was recorded as enthesal thickness, structural changes, bursitis, and power Doppler findings, and MASEI-Damage score was recorded as calcifications and erosions (Figures 1, 2).²³

Statistical analysis

The sample size was calculated with Statstodo (<https://www.statstodo.com/>) and calculated as 84, with a correlation coefficient of 0.3, a margin of error of 0.05, and power (1-B) of 0.8. Considering data loss, the required sample size was accepted as 90.

Statistical analysis was performed using the IBM SPSS version 19.0 software (IBM Corp., Armonk, NY, USA). Normality distribution was assessed by the Kolmogorov-Smirnov test. Mean, standard deviation, median, and range were used to present descriptive analyses. All of the continuous variables except for MCS, PCS, and ASDAS-CRP were distributed asymmetrically. Because of asymmetrical distribution, nonparametric tests were applied. The Mann-Whitney U test was used to compare continuous variables between two groups. Spearman's correlation coefficient was used to analyze the relation between two continuous variables. A p-value <0.05 was considered statistically significant. The Bonferroni correction was used to calculate the adjusted p-value.

RESULTS

Eighty patients were ankylosing spondylitis, and 10 were nonradiographic axial spondyloarthritis. Fifty-four percent of patients were using biologic drugs. The mean body mass index was 26.04±4.2. Median disease duration and diagnostic delay were 12 and 4 years, respectively. Median CRP, ESR, BASDAI, ASDAS-ESR, BASFI, and ASQoL values and mean ASDAS-CRP, PCS and MCS scores are shown in Table 1.

Enthesitis evaluation

A total of 2,610 enthesal sites were examined clinically and 1,080 were assessed via US. The proportion of total enthesal sites (peripheral and axial) exhibiting clinically detectable enthesitis was 413/2,610 (15%). Although at least one enthesitis was detected in all patients in the ultrasonographic enthesal evaluation, no enthesitis was detected in 35 (38%) of the patients in the clinical examination. The median score of both MASES and SPARCC was 2.

The proportions of peripheral enthesal sites exhibiting clinically and ultrasonographically detectable enthesitis were 262/1,620 (16 %) and 635/1,080 (58%), respectively. Hence, 463/1,080 (42%) enthesitis detected by US were not clinically detected. The most frequent US findings were calcification (32%) and an increase in thickness (25%). The two most frequently ultrasonographically involved enthesis sites are the proximal patellar enthesis (149/180; 82%) and Achilles enthesis (146/180; 81%). The least sonographic involvement was observed in plantar aponeurosis (52/180; 28%). Ultrasonographic involvement in triceps enthesis was 86/180 (47%). Median (range) MASEI, MASEI-Inflammatory, MASEI-Damage, and MASEI-Doppler were 16 (1-68), 9 (0-31), 7 (0-38), and 3 (0-21), respectively. The correlation of clinical parameters and clinical enthesitis scores is given in Table 2. Both MASES and SPARCC were correlated with BASDAI, ASDAS, BASFI, ASQoL, MCS, and PCS. There was no correlation between clinical enthesitis score and CRP and ESR.

The comparisons of clinical parameters, clinical enthesitis scores, and US scores are presented in Table 3. There was no correlation between BASDAI, ASDAS-ESR, MASES,




Figure 1. Gray-scale findings in ultrasound. In the distal patellar tendon **(a)**, hypoechogenicity, increase in thickness, and loss of fibrillar pattern are shown. In the proximal patellar tendon **(b)**, Doppler signal accompanying structural findings is noteworthy. Calcification are visible in longitudinal **(c)** and transverse **(d)** planes. Infrapatellar bursitis is present in longitudinal **(e)** and transverse **(f)** planes. Erosion are observed in the longitudinal **(g)** and transverse **(h)** planes.




Figure 2. Ultrasonographic power Doppler findings. **(a, b)** Power Doppler signals are visible at transverse and longitudinal planes. **(c, d)** Signals are also present adjacent to tendon and bursa.

	Mean±SD	Median	Min-Max
CRP (mg/L)		2.64	0.02-44
ESR		8	1-52
BASDAI		3.5	1-7.9
ASDAS-CRP	3.5±1.17		
ASDAS-ESR		2.2	0.9-5.3
BASFI		2.5	1-7.6
ASQoL		7	0-18
Mental Component Score	44.1±11.2		
Physical Component Score	41.7±9.07		

SD: Standard deviation; CRP: C-reactive protein; ESR: Erythrocyte sedimentation rate; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; ASDAS: Ankylosing Spondylitis Disease Activity Score; BASFI: Bath Ankylosing Spondylitis Functional Index; ASQoL: Ankylosing Spondylitis Quality of Life Questionnaire.

Table 2. Correlations of clinical parameters and clinical enthesitis scores

	MASES		SPARCC	
	Spearman correlation results	Correlation coefficient	Spearman correlation results	Correlation coefficient
CRP	0.871	-0.017	0.791	-0.030
ESR	0.099	0.176	0.240	0.135
BASDAI	0.000	0.477	0.000	0.511
ASDAS-CRP	0.036	0.222	0.023	0.256
ASDAS-ESR	0.000	0.363	0.000	0.400
BASFI	0.000	0.384	0.000	0.396
ASQoL	0.000	0.511	0.000	0.498
Physical Component Score	0.000	-0.571	0.000	-0.495
Mental Component Score	0.012	-0.264	0.013	-0.280

CRP: C-reactive protein; ESR: Erythrocyte sedimentation rate; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; ASDAS: Ankylosing Spondylitis Disease Activity Score; BASFI: Bath Ankylosing Spondylitis Functional Index; ASQoL: Ankylosing Spondylitis Quality of Life Questionnaire; MASES: Maastricht Ankylosing Spondylitis Enthesitis Score; SPARCC: Spondyloarthritis Research Consortium of Canada Enthesitis Score Patients.

Table 3. Correlations of clinical parameters, clinical enthesitis scores, and ultrasonographic enthesitis score

	MASEI		MASEI-Damage		MASEI-Inflammatory		MASEI-Doppler	
CRP	0.001*	0.348‡	0.028*	0.232‡	0.000*	0.362‡	0.019*	0.246‡
ESR	0.196*	0.138‡	0.057*	0.202‡	0.923*	0.010‡	0.533*	0.067‡
BASDAI	0.373*	0.095‡	0.743*	0.035‡	0.353*	0.099‡	0.413*	0.087‡
ASDAS-CRP	0.005*	0.294‡	0.084*	0.294‡	0.003*	0.308‡	0.052*	0.206‡
ASDAS-ESR	0.150*	0.137‡	0.206*	0.116‡	0.380*	0.082‡	0.651*	0.033‡
BASFI	0.021*	0.244‡	0.039*	0.217‡	0.054*	0.204‡	0.188*	0.140‡
ASQoL	0.278*	0.116‡	0.395*	0.091‡	0.318*	0.106‡	0.063*	0.197‡
MCS	0.802*	0.027‡	0.671*	0.045‡	0.829*	-0.023‡	0.352*	-0.099‡
PCS	0.202*	-0.136‡	0.598*	-0.056‡	0.137*	-0.158‡	0.066*	-0.194‡
MASES	0.903*	-0.013‡	0.658*	-0.047‡	0.854*	0.020‡	0.088*	0.181‡
SPARCC	0.241*	0.133‡	0.246*	0.132‡	0.357*	0.105‡	0.085*	0.195‡

* Spearman correlation p value is seen; ‡ Correlation coefficients seen parenthetically; CRP: C-reactive protein; ESR: Erythrocyte sedimentation rate; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; ASDAS: Ankylosing Spondylitis Disease Activity Score; BASFI: Bath Ankylosing Spondylitis Functional Index; ASQoL: Ankylosing Spondylitis Quality of Life Questionnaire; MCS: Mental Component Score; PCS: Physical Component Score; MASES: Maastricht Ankylosing Spondylitis Enthesitis Score; SPARCC: Spondyloarthritis Research Consortium of Canada Enthesitis Score Patients; MASEI: Madrid Sonographic Enthesitis Index.

SPARCC, ASQoL, MCS, PCS, and sonographic scores ($p>0.05$). ASDAS-CRP was moderately correlated with MASEI ($r=0.294$) and MASEI-Inflammatory ($r=0.308$) scores ($p<0.01$). There was a moderate correlation between the BASFI score and MASEI ($r=0.244$) and MASEI-Damage ($r=0.217$; $p<0.05$). CRP was moderately correlated with all sonographic scores.

The patients were classified in accordance with cut-off values of CRP values and disease activity scales. The values of subgroups were compared to greyscale findings and sonographic scores (Table 4). The number of cases that had an ASDAS-CRP <1.3 and an ASDAS-ESR >3.5 was inadequate to investigate (two and six, respectively); therefore, the mentioned groups

Table 4. Comparison of clinical and laboratory parameters and ultrasonography lesion and scores

	ASDAS-ESR		ASDAS-CRP		BASDAI	CRP
	<1.3 vs. >1.3	<2.1 vs. >2.1	<2.1 vs. >2.1	<3.5 vs. >3.5	<4 vs. >4	<5 vs. >5
Number of patients	14 vs. 76	43 vs. 47	12 vs. 78	45 vs. 45	59 vs. 31	60 vs. 30
Structure*	0.736	0.241	0.054	0.017	0.119	0.150
Thickness*	0.507	0.586	0.026	0.063	0.365	0.051
Bursitis*	0.077	0.103	0.302	0.368	0.172	0.661
Erosion*	0.707	0.660	0.281	0.153	0.183	0.524
Calcification*	0.963	0.895	0.077	0.810	0.387	0.388
MASEI*	0.475	0.711	0.009	0.052	0.350	0.020
MASEI-I*	0.478	0.947	0.009	0.039	0.247	0.011
MASEI-D*	0.967	0.621	0.036	0.275	0.855	0.167
MASEI-PD*	0.549	0.330	0.143	0.418	0.588	0.122

ASDAS: Ankylosing Spondylitis Disease Activity Score; ESR: Erythrocyte sedimentation rate; CRP: C-reactive protein; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; MASEI: Madrid Sonographic Enthesitis Index; MASEI-I: MASEI-Inflammatory; MASEI-D: MASEI-Damage; MASEI-PD: MASEI-power Doppler; * P values are given.

could not be compared. No significant difference was found in comparisons made in both ASDAS and BASDAI subgroups. There were significant differences between the patients with ASDAS-CRP above and below 2.1 in thickness scores and in all US scores except for Doppler scores. There were significant differences in structure and MASEI-Inflammatory scores between the patients with ASDAS-CRP above and below 3.5. Those with CRP values >5 had significantly higher MASEI and MASEI-Inflammatory scores.

DISCUSSION

Enthesitis is one of the most characteristic lesions of SpA and plays an important role in its pathogenesis. US is highly valuable in evaluating enthesitis as an “organ complex.”²⁴ It has been shown that the evaluation of entheses with US is helpful and reliable in diagnosing SpA.²⁵ In patients with SpA, it is complicated to evaluate clinical parameters such as disease activity and quality of life, and US may assist physicians to obtain accurate answers. In our study, we found that US detected 463 (42%) sites of enthesitis that were missed by clinical examination, and the US scores moderately correlated with the CRP level, ASDAS-CRP, and BASFI score compared

to the disease-related parameters in patients with SpA.

Several studies have demonstrated that a US examination is better and more sensitive for detecting enthesitis than a clinical examination.^{9,26,27} Ruta et al.²⁸ detected 60.8% (331/544 enthesal sites) asymptomatic enthesitis on US examination. Our study findings are in agreement as we also detected a significant proportion of enthesitis (42%) missed during a clinical examination. Thus, there are evidently a considerable number of sites with subclinical enthesitis involvement that can be detected by US. These results indicate that US should be a part of the diagnostic evaluation in rheumatology departments, particularly for patients with SpA.

In our study, the most frequently affected entheses were the proximal patellar tendon and the Achilles tendon, while the least involved was the plantar aponeurosis. The reason for the lesser detection of plantar aponeurosis enthesitis may be the difficulty in US evaluation of this site. While other entheses are located superficially, excessive skin thickness and the heel fat pad make the location of the plantar aponeurosis deeper. Since the involvement of the lower extremities is more common in patients with SpA, the upper extremity entheses may be neglected clinically.

Studies evaluating entheses by US examination initially only included the lower extremity sites; however, recent studies have started including the upper extremity sites for a more thorough enthesitis evaluation.^{9,10} Our study also highlighted a significant involvement in the distal triceps tendon (47%). It is recommended that upper extremity sites should not be ignored in clinical and radiological evaluation of entheses.

In the present study, clinical enthesitis evaluation was performed with both MASES, which mostly evaluates axial entheses, and SPARCC, which evaluates only peripheral entheses. Clinical enthesitis scores have been found to be correlated with clinical parameters in previous studies.²⁹⁻³¹ In the present study, it was found that MASES and SPARCC were correlated with other clinical parameters, but not with acute phase reactants. In previous studies, no correlation was found between acute phase reactants and clinical enthesitis scores.^{6,26} The probable reason for the correlation between clinical enthesitis scores and clinical parameters is that these evaluations are subjective and based on the patient's response.¹⁶ Peripheral entheses can be easily evaluated on US, and SPARCC has been used to compare clinical and sonographic evaluation of enthesitis. In previous studies, both BUSES and lower extremity enthesitis scores were found to be correlated with SPARCC.^{16,17} Since the sonographic evaluation of axial entheses is relatively troublesome, it was wondered whether the ultrasonographic evaluation of peripheral entheses would be associated with a clinical axial enthesitis score. If the association was detected, only US peripheral evaluation might have been adequate to show also axial enthesitis. However, no correlation was found between clinical and ultrasonographic enthesitis scores in the present study. Although it was found to be correlated with lower extremity enthesitis score and MASEI,^{16,32} we believe that sonographic peripheral enthesitis evaluation may not reflect axial enthesitis. Only bilateral Achilles entheses, which are included in MASES, are a part of MASEI. As far as we know, no sonography score for the evaluation of axial entheses has been developed yet. It is believed that adding axial enthesitis, such as costochondral enthesitis, may provide a better correlation with axial entheses.

Although the values of both CRP level and ESR are elevated in patients with SpA, the CRP levels are more indicative. Elevated CRP levels

have been found to be associated with increased disease activity, good response to treatment, and radiological progression.³³⁻³⁵ In our study, we did find that CRP levels moderately correlated with all the US scores. Studies evaluating the correlation of the US scores with CRP levels and ESR have shown variable results. Some studies have failed to show any correlation;^{9,12,17,18,36,37} however, in agreement with our study, few studies have found a relationship between the US scores and CRP levels.³⁸⁻⁴⁰ CRP is an objective marker of active disease in SpA, and a moderate correlation between the US scores and CRP levels may indicate the role of US score as a potential marker of active disease.

Measuring "real disease state" is generally difficult, particularly in SpA. Although enthesitis plays an important role in its pathogenesis, it is frequently ignored in the evaluation of real disease states. In our study, we evaluated enthesitis in SpA patients and did not find any significant relationship between the US enthesitis scores and disease activity scales other than ASDAS-CRP. ASDAS-CRP was moderately correlated with the MASEI and MASEI-Inflammatory scores (correlation coefficients of 0.294 and 0.308, respectively). Most of the previous studies have failed to show any correlation between US and BASDAI,^{12,17,36,38,39,41,42} besides a few studies.^{18,19,40} Although these studies may suggest that US may be insufficient for disease activity evaluation, some authors have also argued that the current disease activity scales may be inadequate in expressing the real disease state.^{43,44} BASDAI is a subjective measure of symptoms and is based on patients' responses on a self-administered questionnaire; hence, the score may be affected by other concurrent pain-causing illnesses, such as chronic pain and fibromyalgia. We speculated that the reason for the correlation between the US scores and ASDAS-CRP in our study is that it includes the objective inflammatory scale and CRP level. The other disease activity scales included in the study are subjective in nature and might not represent the true disease activity. We recommend that new SpA disease activity scales, perhaps incorporating US scores, should be developed.

In our study, we also investigated which ultrasonographic lesion or score was associated with subgroups of disease activity scores and CRP. Falcao et al.¹⁵ aimed to find out which elemental lesion and the score of Achilles enthesitis was associated with cut-off values of ASDAS, BASDAI, and CRP. They

did find that the Doppler signal and structure of the Achilles tendon were significantly associated with higher CRP. In our study, there was no association between higher CRP values and elemental lesions. Patients with higher CRP (>5) had higher MASEI and MASEI-Inflammatory scores but not higher MASEI-Doppler scores in the present study. Our results may suggest that evaluating only Doppler signals is insufficient to reveal real inflammation. Elementary lesions, such as structural change, thickness, and accompanying bursitis, that give MASEI-Inflammatory scores should be evaluated as a whole since none of them were found to be correlated with CRP elevation alone. When the disease activity scores were compared according to cut-off values, no difference was found between the sonographic lesions and scores in the BASDAI and ASDAS-ESR subgroups. Falcao et al.¹⁵ did find that patients with very high disease activity (ASDAS-CRP >3.5), and high disease activity (BASDAI >4) had a significantly higher Achilles US score. None of the elementary lesions in Achilles enthesitis were associated with BASDAI or ASDAS.¹⁵ In the ASDAS-CRP subgroups, the thickness scores were found to be significantly higher in patients who had ASDAS-CRP >2.1, and the structure scores were found to be significantly higher in those with very high disease activity (ASDAS-CRP >3.5). Sonography scores except for MASEI Doppler were detected to be significantly higher in patients with ASDAS-CRP >2.1. However, only the MASEI-Inflammatory score was significantly different between patients with and without very high disease activity. Based on these results, it could be suggested that the MASEI-Inflammatory score may be sufficient and a time saver to evaluate real-time disease activity.

Spondyloarthritis is a disease that can cause significant functional loss with joint movement limitation and stiffness. BASFI is often used to evaluate the loss of function in SpA. We found a moderate correlation between the BASFI and MASEI and MASEI-Damage scores. No study other than Milutinovic et al.'s¹⁸ study, evaluating BASFI and various peripheral enthesitis US indices, has reported any correlation between these parameters.^{12,17,36,41} The reason for functional loss in SpA is mainly the involvement of the spine and axial joints. Since we can only evaluate peripheral enthesitis sites via US, it was expected that US scores would moderately correlate with functionality. The

US evaluation of the sacroiliac joint, root joints (shoulder and hip joints), and perhaps even the paravertebral regions may help us obtain a reliable score that correlates with functionality.

Studies that evaluate the relation between the quality of life scales (ASQoL or SF-12) and US scores are limited. In our study, we did not find any correlation between the quality of life scales and US scores. Similar to our results, Falcao et al.⁴¹ found no correlation between US findings and ASQoL. Hamdi et al.¹⁶ found that Doppler scores were correlated with ASQoL. Suleyman et al.¹⁹ found a moderately significant correlation between ASQoL and MASEI. Nonetheless, further studies are needed to provide adequate information on this subject.

OMERACT defines enthesitis as a “hypoechoic and/or thickened insertion of the enthesis close to the bone (within 2 mm from the bony cortex) which exhibits Doppler signal if active and that may show erosions, enthesophytes/calcifications as a sign of structural damage.” In the present study, enthesitis was identified as the presence of one of the elemental lesions that met the definition regardless of the US score. The reliability of the OMERACT US Task Force’s definition of enthesitis was investigated on a web-based using images and videos.⁴⁵ The results underlined that bone erosions, power Doppler signal, and enthesophytes/calcifications showed good reliability, but the reliability of thickness and hypoechoogenicity was low. The normal thickness changes with age, sex, and body mass index, and the evaluation of thickness may be affected by position, location, and the type of enthesitis; consequently, the threshold to name a tendon as thickened is not clear.⁴⁶ More focal and less distinct regions of hypoechoogenicity may be confusing. The definitions of the lesions or enthesitis need to be clarified. The absence of a threshold for enthesitis in any sonographic score, including MASEI, may lead us to overdiagnose. Due to the absence of a gold standard imaging technique to detect enthesitis, it is uncertain which sonographic score defines enthesitis.

In our study, the evaluation of enthesitis was performed only by US, which is insufficient to assess bone marrow edema, a part of enthesitis pathophysiology. MRI may be the best modality to evaluate bone marrow edema but makes simultaneous and multiple joint evaluations

challenging. It has been reported that the US and MRI findings provide dissimilar information, making it challenging to determine which of these constitutes the standard method in the enthesitis evaluation.⁴⁷ In the present study, the MASEI scoring system, widely used in US examinations, was utilized. However, MASEI includes evaluation of the plantar aponeurosis, which is difficult to evaluate, and a single upper limb site (the distal triceps tendon) for enthesitis evaluation. Belgrade Ultrasound Enthesis Score, developed later than MASEI, also includes plantar aponeurosis and a single upper extremity site (common extensor tendon) for enthesitis evaluation. Additionally, its sensitivity and specificity are lower than those of the MASEI scoring system.¹⁴ We believed that new sonographic scoring systems need to evaluate more than one upper extremity entheses.

There are some limitations to this study. One of the limitations of our study is the evaluation of peripheral enthesitis sites alone. We recommend including joint evaluation, particularly the sacroiliac joint, and axial enthesitis sites, such as paravertebral and costochondral regions, in the US examination in future studies. Nonetheless, a scoring system examining all the aspects of SpA has not been developed yet and is limited to scores based on enthesitis evaluation. In the present study, only MASEI was compared with the clinical parameters. Other sonographic scores could also be utilized, and it could be determined which sonographic score is better at revealing the real disease state. Another limitation of our study is that the presence of concomitant fibromyalgia was not questioned. Fibromyalgia significantly affects the results of the scales based on the subjective complaints of the person. In studies in which the presence of fibromyalgia is an exclusion criterion, ultrasonographic enthesitis scores may be correlated with other clinical parameters, such as quality of life and BASDAI. Finally, the lack of sample size is also a limitation of our study.

In conclusion, it is well known that US is a better and more sensitive method of evaluation of enthesitis than clinical examination. US assessment should be a part of disease evaluation in SpA patients. The association of US scores with CRP levels and ASDAS-CRP may indicate that US is sensitive to inflammation. The MASEI score moderately correlates with functionality but not with quality of life. New disease activity scores with more

objective markers are needed in SpA, incorporating invaluable ultrasonographic evaluation parameters.

Ethics Committee Approval: The study protocol was approved by the Cerrahpaşa Faculty of Medicine Clinical Research Ethics Committee (date: 22.09.2016, no: 83045809-604.01.02). The study was conducted in accordance with the principles of the Declaration of Helsinki.

Patient Consent for Publication: A written informed consent was obtained from each patient.

Data Sharing Statement: The data that support the findings of this study are available from the corresponding author upon reasonable request.

Author Contributions: Idea/concept G.E., D.P., K.A., H.S.; Design, Data collection and/or processing, writing the article: G.E., D.P., I.A.; Control/supervision: K.A., H.S.; Analysis and/or interpretation: G.E., K.A., H.S.; Literature review: G.E., I.A.; Critical review, materials: D.P., K.A., H.S.; References and fundings: G.E., I.A., D.P.

Conflict of Interest: The authors declared no conflicts of interest with respect to the authorship and/or publication of this article.

Funding: The authors received no financial support for the research and/or authorship of this article.

REFERENCES

1. McGonagle D, Benjamin M. Enthesopathies. In: Hochberg MC, Smolen JS, Weisman MH, Silman AJ, Weinblatt ME, editors. *Rheumatology*. 6th ed. Philadelphia: Mosby; 2015. p. 1014-20.
2. Stavre Z, Bridgwood C, Zhou Q, Maeda Y, Huang TT, Karman J, et al. A role for neutrophils in early enthesitis in spondyloarthritis. *Arthritis Res Ther* 2022;24:24. doi: 10.1186/s13075-021-02693-7.
3. De Lorenzis E, Natalello G, Simon D, Schett G, D'Agostino MA. Concepts of enthesal pain. *Arthritis Rheumatol* 2023;75:493-8. doi: 10.1002/art.42299.
4. Mander M, Simpson JM, McLellan A, Walker D, Goodacre JA, Dick WC. Studies with an enthesitis index as a method of clinical assessment in ankylosing spondylitis. *Ann Rheum Dis* 1987;46:197-202. doi: 10.1136/ard.46.3.197.
5. Heuft-Dorenbosch L, Spoorenberg A, van Tubergen A, Landewé R, van der Tempel H, Mielants H, et al. Assessment of enthesitis in ankylosing spondylitis. *Ann Rheum Dis* 2003;62:127-32. doi: 10.1136/ard.62.2.127.
6. Maksymowych WP, Mallon C, Morrow S, Shojania K, Olszynski WP, Wong RL, et al. Development and validation of the Spondyloarthritis Research

- Consortium of Canada (SPARCC) Enthesitis Index. *Ann Rheum Dis* 2009;68:948-53. doi: 10.1136/ard.2007.084244.
7. Desai N, Baker JF, Bucci J, Kissin EY. Ultrasound evaluation of the Achilles enthesis in inflammatory and non-inflammatory processes: A systematic review and meta-analysis. *Clin Exp Rheumatol* 2023;41:24-31. doi: 10.55563/clinexprheumatol/6vg24c.
 8. Lehtinen A, Taavitsainen M, Leirisalo-Repo M. Sonographic analysis of enthesopathy in the lower extremities of patients with spondylarthropathy. *Clin Exp Rheumatol* 1994;12:143-8.
 9. Balint PV, Kane D, Wilson H, McInnes IB, Sturrock RD. Ultrasonography of enthesal insertions in the lower limb in spondyloarthropathy. *Ann Rheum Dis* 2002;61:905-10. doi: 10.1136/ard.61.10.905.
 10. D'Agostino MA, Said-Nahal R, Hacquard-Bouder C, Brasseur JL, Dougados M, Breban M. Assessment of peripheral enthesitis in the spondylarthropathies by ultrasonography combined with power Doppler: A cross-sectional study. *Arthritis Rheum* 2003;48:523-33. doi: 10.1002/art.10812.
 11. Bruyn GA, Iagnocco A, Naredo E, Balint PV, Gutierrez M, Hammer HB, et al. OMERACT definitions for ultrasonographic pathologies and elementary lesions of rheumatic disorders 15 years on. *J Rheumatol* 2019;46:1388-93. doi: 10.3899/jrheum.181095.
 12. Alcalde M, Acebes JC, Cruz M, González-Hombrado L, Herrero-Beaumont G, Sánchez-Pernaute O. A sonographic enthesitic index of lower limbs is a valuable tool in the assessment of ankylosing spondylitis. *Ann Rheum Dis* 2007;66:1015-9. doi: 10.1136/ard.2006.062174.
 13. de Miguel E, Muñoz-Fernández S, Castillo C, Cobo-Ibáñez T, Martín-Mola E. Diagnostic accuracy of enthesitis ultrasound in the diagnosis of early spondyloarthritis. *Ann Rheum Dis* 2011;70:434-9. doi: 10.1136/ard.2010.134965.
 14. Milutinovic S, Radunovic G, Veljkovic K, Zlatanovic M, Zlatkovic Svenda M, Perovic Radak M, et al. Development of ultrasound enthesitis score to identify patients with enthesitis having spondyloarthritis: Prospective, double-blinded, controlled study. *Clin Exp Rheumatol* 2015;33:812-7.
 15. Falcao S, Castillo-Gallego C, Peiteado D, Branco J, Martín Mola E, de Miguel E. Can we use enthesitis ultrasound as an outcome measure of disease activity in spondyloarthritis? A study at the Achilles level. *Rheumatology (Oxford)* 2015;54:1557-62. doi: 10.1093/rheumatology/keu399.
 16. Hamdi W, Chelli-Bouaziz M, Ahmed MS, Ghannouchi MM, Kaffel D, Ladeb MF, et al. Correlations among clinical, radiographic, and sonographic scores for enthesitis in ankylosing spondylitis. *Joint Bone Spine* 2011;78:270-4. doi: 10.1016/j.jbspin.2010.09.010.
 17. Florescu A, Pădureanu V, Florescu DN, Bobircă A, Florescu LM, Bumbea AM, et al. The Role of clinical and ultrasound enthesitis scores in ankylosing spondylitis. *Life (Basel)* 2021;11:218. doi: 10.3390/life11030218.
 18. Milutinovic S, Radunovic G, Veljkovic K, Zlatanovic M, Damjanov N. Construct validity and sensitivity to change of Belgrade Ultrasound Enthesitis Score in patients with spondyloarthritis: A pilot study. *Rheumatol Int* 2018;38:383-91. doi: 10.1007/s00296-017-3898-8.
 19. Süleyman E, Nas K, Harman H, Kaban N. Clinical and ultrasonographic enthesopathy in inflammatory rheumatic diseases : Is MASEI or only calcaneal enthesitis sufficient? *Z Rheumatol* 2018;77:719-26. doi: 10.1007/s00393-017-0405-2.
 20. Rudwaleit M, van der Heijde D, Landewé R, Listing J, Akkoc N, Brandt J, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): Validation and final selection. *Ann Rheum Dis* 2009;68:777-83. doi: 10.1136/ard.2009.108233.
 21. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. *Arthritis Rheum* 1984;27:361-8. doi: 10.1002/art.1780270401.
 22. de Miguel E, Cobo T, Muñoz-Fernández S, Naredo E, Usón J, Acebes JC, et al. Validity of enthesitis ultrasound assessment in spondyloarthropathy. *Ann Rheum Dis* 2009;68:169-74. doi: 10.1136/ard.2007.084251.
 23. Mata Arnaiz MC, de Miguel Mendieta E. Usefulness of ultrasonography in the assessment of peripheral enthesitis in spondyloarthritis. *Reumatol Clin* 2014;10:113-9. doi: 10.1016/j.reuma.2013.11.004.
 24. D'Agostino MA. Role of ultrasound in the diagnostic work-up of spondyloarthritis. *Curr Opin Rheumatol* 2012;24:375-9. doi: 10.1097/BOR.0b013e328354612f.
 25. Ozsoy-Unubol T, Yagci I. Is ultrasonographic enthesitis evaluation helpful for diagnosis of non-radiographic axial spondyloarthritis? *Rheumatol Int* 2018;38:2053-61. doi: 10.1007/s00296-018-4164-4.
 26. Klauser AS, Wipfler E, Dejaco C, Moriggl B, Duftner C, Schirmer M. Diagnostic values of history and clinical examination to predict ultrasound signs of chronic and acute enthesitis. *Clin Exp Rheumatol* 2008;26:548-53.
 27. Spadaro A, Iagnocco A, Perrotta FM, Modesti M, Scarno A, Valesini G. Clinical and ultrasonography assessment of peripheral enthesitis in ankylosing spondylitis. *Rheumatology (Oxford)* 2011;50:2080-6. doi: 10.1093/rheumatology/ker284.
 28. Ruta S, Gutierrez M, Pena C, García M, Arturi A, Filippucci E, et al. Prevalence of subclinical enthesopathy in patients with spondyloarthropathy: An ultrasound study. *J Clin Rheumatol* 2011;17:18-22. doi: 10.1097/RHU.0b013e318204a6f8.
 29. Turan Y, Duruöz MT, Cerrahoglu L. Relationship between enthesitis, clinical parameters and quality

- of life in spondyloarthritis. *Joint Bone Spine* 2009;76:642-7. doi: 10.1016/j.jbspin.2009.03.005.
30. Laatiris A, Amine B, Ibn Yacoub Y, Hajjaj-Hassouni N. Enthesitis and its relationships with disease parameters in Moroccan patients with ankylosing spondylitis. *Rheumatol Int* 2012;32:723-7. doi: 10.1007/s00296-010-1658-0.
 31. Inal EE, Eroglu P, Sunar İ, Canak S, Yener M. May we use enthesitis indices in evaluating disease activity in patients with ankylosing spondylitis?. *Acta Medica Mediterranea* 2014;30:1305-10.
 32. Atzeni F, Batticciotto A, Salli S, Antivalle M, Sarzi-Puttini P. Use of ultrasonography in patients with inflammatory bowel disease and spondyloarthritis: An update. *Rheumatol Curr Res* 2012;S2:008. doi:10.4172/2161-1149.S2-008.
 33. Rudwaleit M, van der Heijde D, Landewé R, Akkoc N, Brandt J, Chou CT, et al. The assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. *Ann Rheum Dis* 2011;70:25-31. doi: 10.1136/ard.2010.133645.
 34. Poddubnyy D, Haibel H, Listing J, Märker-Hermann E, Zeidler H, Braun J, et al. Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. *Arthritis Rheum* 2012;64:1388-98. doi: 10.1002/art.33465.
 35. Rudwaleit M, Haibel H, Baraliakos X, Listing J, Märker-Hermann E, Zeidler H, et al. The early disease stage in axial spondylarthritis: Results from the German Spondyloarthritis Inception Cohort. *Arthritis Rheum* 2009;60:717-27. doi: 10.1002/art.24483.
 36. Naredo E, Batlle-Gualda E, García-Vivar ML, García-Aparicio AM, Fernández-Sueiro JL, Fernández-Prada M, et al. Power Doppler ultrasonography assessment of entheses in spondyloarthropathies: Response to therapy of enthesal abnormalities. *J Rheumatol* 2010;37:2110-7. doi: 10.3899/jrheum.100136.
 37. Borman P, Koparal S, Babaoğlu S, Bodur H. Ultrasound detection of enthesal insertions in the foot of patients with spondyloarthropathy. *Clin Rheumatol* 2006;25:373-7. doi: 10.1007/s10067-005-0036-x.
 38. Aydin SZ, Karadag O, Filippucci E, Atagunduz P, Akdogan A, Kalyoncu U, et al. Monitoring Achilles enthesitis in ankylosing spondylitis during TNF-alpha antagonist therapy: An ultrasound study. *Rheumatology (Oxford)* 2010;49:578-82. doi: 10.1093/rheumatology/kep410.
 39. Ruta S, Acosta Felquer ML, Rosa J, Navarta DA, García Monaco R, Soriano ER. Responsiveness to therapy change of a global ultrasound assessment in spondyloarthritis patients. *Clin Rheumatol* 2015;34:125-32. doi: 10.1007/s10067-014-2673-4.
 40. Hu Z, Xu M, Wang Q, Qi J, Lv Q, Gu J. Colour Doppler ultrasonography can be used to detect the changes of sacroiliitis and peripheral enthesitis in patients with ankylosing spondylitis during adalimumab treatment. *Clin Exp Rheumatol* 2015;33:844-50.
 41. Falcao S, de Miguel E, Castillo-Gallego C, Peiteado D, Branco J, Martín Mola E. Achilles enthesitis ultrasound: The importance of the bursa in spondyloarthritis. *Clin Exp Rheumatol* 2013;31:422-7.
 42. Ezzat Y, Gaber W, Abd EL-Rahman SF, Ezzat M, El Sayed M. Ultrasonographic evaluation of lower limb entheses in patients with early spondyloarthropathies. *Egypt Rheumatol* 2013;35:29-35. doi: 10.1016/j.ejr.2012.09.004.
 43. Blasco-Blasco M, Castrejón I, Jovaní V, Pascual E, Ruiz-Cantero MT. Reviewing disease activity indices in spondyloarthritis from the sex perspective: a systematic review and metaanalysis. *J Rheumatol* 2021;48:1395-1404. doi: 10.3899/jrheum.200967.
 44. Michielsens C, Bolhuis TE, van Gaalen FA, van den Hoogen F, Verhoef LM, den Broeder N, den Broeder AA. Construct validity of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Ankylosing Spondylitis Disease Activity Score (ASDAS) treatment target cut-offs in a BASDAI treat-to-target axial spondyloarthritis cohort: a cross-sectional study. *Scand J Rheumatol* 2023;1-8. [Online ahead of print] doi: 10.1080/03009742.2023.2213509.
 45. Di Matteo A, Cipolletta E, Destro Castaniti GM, Smerilli G, Airoldi C, Aydin SZ, et al. Reliability assessment of the definition of ultrasound enthesitis in SpA: Results of a large, multicentre, international, web-based study. *Rheumatology (Oxford)* 2022;61:4863-74. doi: 10.1093/rheumatology/keac162.
 46. Almeida DE, Wakefield RJ. Assessing enthesitis using ultrasound: Unfinished business. *Rheumatology (Oxford)* 2022;61:4581-2. doi: 10.1093/rheumatology/keac380.
 47. Aydin SZ, Tan AL, Hodsgon R, Grainger A, Emery P, Wakefield RJ, et al. Comparison of ultrasonography and magnetic resonance imaging for the assessment of clinically defined knee enthesitis in spondyloarthritis. *Clin Exp Rheumatol* 2013;31:933-6.